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Abstract: The use of cyclosporin is well established within the ophthalmology community, 
especially against sight threatening intra-ocular inﬂ  ammation. It is well known however, that 
immunosuppression in general is a risk factor for the development of malignancy and numerous 
studies point to the risk imposed by cyclosporin. This article analyses and reviews all relevant 
studies with regard to the development of malignancy associated with the use of cyclosporin 
and extrapolates this into the ophthalmic setting. This is to enable clinicians to assess the risks 
in individual patients and to present a monitoring regime which can be used in patients undergo-
ing cyclosporin treatment. The review is solely concerned with the risk of the development of 
malignancy following cyclosporin immunosuppression and not with any other adverse effect.
Keywords: cyclosporin, ciclosporine, cyclosporine, malignancy, neoplasm and cancer 
development
Background
Uncontrolled ocular inﬂ  ammation is an important cause of visual loss. The incidence 
of blindness due to uveitis is, for example, similar to that due to diabetic retinopathy 
amongst people of working age (Tremblay et al 2002). 70% of patients attending a 
uveitis clinic have been reported to have vision worse than 6/18 (Durrani et al 2004). 
In order to prevent or treat these potentially blinding conditions, a variety of drugs are 
used to suppress the immune response. Traditionally corticosteroids have been used 
but in more recent years the use of cyclosporin A (CsA) has become more widespread 
as monotherapy or in combination with other immunosuppressive agents.
The discovery of the immunosuppressive action of CsA in 1976 by Borel et al (1976, 
1977) began a new era in immunopharmacology. It was the ﬁ  rst immunosuppressive 
drug that allowed selective immunoregulation of T cells without excessive toxicity. 
It is now commonly used for immunosuppression following organ transplantation, 
treatment of graft-versus-host reactions following bone marrow transplantation, in 
the treatment of rheumatoid disease, psoriasis and severe forms of atopic disease. Its 
use in ophthalmology is well established.
CsA use is associated with several signiﬁ  cant adverse reactions. Most of these, such 
as its effects on renal function or blood pressure, are well recognized and regimes for 
monitoring patients on CsA are well established. The risk of the development of malig-
nancy is however, a very important consideration and it is not uncommon following 
organ transplantation. The risk of the development of malignancy associated with the 
use of CsA in an ophthalmic setting is not clear. This review aims to collate previous 
studies regarding the development of malignancy and suggest guidelines that should 
be adhered to when commencing this treatment in the ophthalmology setting.
Literature review
A literature search was carried out into cyclosporin and malignancy using the Medline 
search engine. There is no relevant publication in the Cochrane library. Several searches 
were performed using combinations of cyclosporin, ciclosporine, cyclosporine, Clinical Ophthalmology 2007:1(4) 422
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malignancy, neoplasm and cancer development. The 
extensive results were ﬁ  ltered for relevancy and all articles 
that were concerned – either primarily or secondarily 
– with malignancy development following the use of CsA 
were reviewed. One non-English language publication was 
encountered and abstract translation was sufﬁ  cient for its 
use. All articles that were considered eligible were analyzed 
and weighted according to the usual hierarchy of evidence 
– RCT’s, cohort studies, case-control studies, cross-sectional 
surveys then case reports.
Mechanism of action
Cyclosporin is a lipophilic, cyclic endecapeptide consisting 
of 11 amino acids and is produced as a metabolite of the 
fungus species Tolypocladium inﬂ  atum and Cylindrocarpon 
lucidium. It was initially discovered by Borel and his 
co-workers in their studies of screening fungal products for 
antifungal activity (Borel et al 1976). Nine cyclosporins 
have been isolated (A to I) but only A, C and G exhibit any 
immunological activity (Yocum 1993). The immunosuppres-
sion caused by CsA is most effective against T cell dependent 
immune mechanisms, which are implicated in transplant 
rejection and some forms of autoimmunity. The immuno-
suppressive activity of CsA is the result of the inhibition 
of T-helper cells and cytotoxic T-cells, suppressor T-cells 
being less affected. CsA blocks cytotoxic T cell activation by 
initially binding to the cyclophilin family of proteins which 
in turns recruits calcineurin, inhibiting its action. This causes 
inhibition of the formation of a calcineurin-dependent fac-
tor, essential for the transcription of the interleukin-2 gene, 
thereby reducing production of IL-2 by activated T cells and 
inhibiting expression of IL-2 receptors by cytotoxic T cells. 
CsA also selectively blocks many immunoregulatory func-
tions of activated T-cells inhibiting the release of IL-3, IL-4, 
IL-5, interferon γ, GM-CSF and TNF-α. A further action of 
CsA is to increase expression of TGF β; a potent inhibitor of 
IL-2 stimulated T cell proliferation and inducer of ﬁ  broblast 
growth. A further mechanism that ampliﬁ  es the immunosup-
pression is the induction of T cell apoptosis which happens 
with most immunosuppression agents.
Cyclosporin can be given orally, by intravenous injection 
or topically. Systemic administration achieves peak plasma 
concentration within 3–4 hours. It has a plasma half-life of 
around 24 hours and plasma concentration can be determined 
by radio-immunoassay. CsA accumulates in most tissues at a 
concentration 3–4 times that measured in the plasma. CsA is 
extensively metabolized in the liver by cytochrome P450 3A 
enzyme and also, to a lesser extent, by the gastrointestinal 
tract and kidneys. The metabolites are mainly excreted via 
the bile into the faeces; however, 6% is excreted via the 
kidneys and 0.1% is excreted unchanged in the urine (Rang 
et al 1990).
Tumor pathogenesis
Longstanding immunosuppression – whether iatrogenic, 
acquired or due to inherent defects of the humoral or cel-
lular immune response – is associated with increased risk of 
malignancy. This is especially true of those tumors where 
oncogenic viruses play a role in the pathogenesis. The com-
monest tumors associated with immunosuppression are skin 
cancers with 90% of these being either squamous (SCC) or 
basal cell carcinomas (BCC) (Euvard et al 2003). SCC has 
been estimated to occur 65–250 times as frequently as in the 
general population and BCC 10 times (Hartevelt et al 1990). 
All SCC’s are more aggressive in immunosuppressed patients 
with more rapid growth, recurrence in 13.4% of patients 
and metastases in 5 to 8% (Euvard et al 2003). Kaposi sar-
coma (KS) is also far commoner in the immunosuppressed 
population. A viral cause of KS was conﬁ  rmed in 1994 by 
the discovery of human herpes virus 8 (HHV-8) and it is the 
geographic distribution of this virus that may be the cause of 
the ethnic differences seen (Boshoff and Weiss 2001).
Lymphoproliferative disease is the second most common 
malignancy in the chronically immunosuppressed but it is 
seen as a far greater risk due to the associated mortality. 
Post transplant lymphoproliferative disorder (PTLD) is a 
spectrum of malignancies that range from mononucleosis 
to frank lymphoma. There is strong evidence linking EBV 
with non-Hodgkin’s lymphoma (Caillard et al 2005), and 
emerging studies linking CNS lymphoma with CMV and 
polyomavirus (Del Valle et al 2004). Immunosuppression is 
heavily implicated in the pathogenesis of PTLD either due 
to the reduced immuno-modulation of EBV, absence of T 
lymphocyte control over benign lymphoproliferation or the 
over-stimulation of a depressed immune system by chronic 
antigen stimulation from transplanted tissue.
It has been estimated that over the next 20 years, post-
transplant malignancy will become the leading cause of 
mortality in solid organ transplant recipients with current 
estimates placing the incidence of malignancy at 20% in 
the chronically immunosuppressed (Guba et al 2004). The 
etiology is very complex and multifactorial, for this review 
we will concentrate on the research implicating CsA. As 
the review shows, CsA may carry a higher risk of some 
malignancies than other immunosuppressive agents, various 
theories have been postulated to account for this.Clinical Ophthalmology 2007:1(4) 423
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Synthesis of TGF-β
CsA promotes cancer progression by inducing TGF-β 
production (Hojo et al 1999). Virtually every cell in the 
body produces and has receptors for TGF-β. This cytokine 
regulates both the proliferation/differentiation of cells and 
stimulates both the production and the adhesiveness of the 
extracellular matrix by stimulating ﬁ  broblasts and other cells 
to produce extracellular matrix proteins and cell adhesion 
proteins. It also decreases the production of enzymes that 
degrade the extracellular matrix, including collagenase, 
heparinase and stromelysin and increases the production of 
proteins that inhibit these enzymes, such as plasminogen-
activator inhibitor type 1 and tissue inhibitor of matrix 
metalloprotease. The net effect is an increase the production 
of extracellular matrix proteins and changes to the adhesive 
properties of cells. In cancer cells the production of TGF-β 
is upregulated, increasing the invasiveness of the cells by 
increasing their proteolytic activity and promoting binding 
to cell adhesion molecules. The production and secretion 
of TGF-β by certain cancer cells suppresses the activities 
of inﬁ  ltrating immune cells, helping the tumor escape host 
immunosurveillance. In addition, animal studies (Guba et al 
2004; Shihab et al 2003) indicate that subsequent tumor 
development may be related to an enhancement of tumor 
angiogenesis possibly due to an increased expression of 
vascular endothelial growth factor (VEGF). Both increased 
production of TGF-β and VEGF will work to enhance tumor 
progression but neither will initiate oncogenesis.
Inhibition of DNA repair
CsA inhibits both Ultraviolet-B induced apoptosis and DNA 
repair in normal keratinocytes following UVB irradiation 
(Yarosh et al 2005; Kelly et al 1987; Herman et al 2001). 
The study by Herman took peripheral blood monocytes 
from renal transplant patients and induced DNA damage by 
UV irradiation. They found that CsA treated patients had 
signiﬁ  cantly poorer DNA repair than those patients treated 
by azathioprine or prednisolone (or in combination). Ahlers 
et al (1999) proved that CsA inhibited the gene coding for 
DNA polymerase Beta – a DNA repair enzyme.
Apoptosis alteration
The published evidence of the action of CsA on apoptosis 
shows that depending on cell type and conditions, CsA can 
induce or inhibit the process. It is well recognised that CsA 
(and immunosuppression in general) can cause apoptosis of 
T cells (Fellstrom and Zezina 2001); however, several studies 
have shown CsA to have a anti-apoptotic effect (Andre et al 
2004) due to its binding with cyclophilin D which in turns 
inhibits a permeability pore opening in mitochondrial inner 
membranes which is the trigger for apoptosis initiation.
All these biochemical actions of CsA theoretically work 
in conjunction with one another to cause and promote cancer 
development. The initial DNA mutation may be caused by 
sunlight (skin tumors) or oncogenic viruses (such as EBV, 
implicated in PTLD and HHV-8 in KS) but CsA causes 
impaired DNA repair leading to mutated DNA. This cell 
should undergo apoptosis but this process can be inhibited 
by CsA and the induction of TGF-β/VEGF works to promote 
tumor progression.
Neoplasms associated with
non-ophthalmic use of CsA
The majority of studies regarding the development of malig-
nancy following CsA use stems from transplantation research. 
Penn’s work (Penn 1987a, 1987b; Penn and Brunson 1988) 
using the Cincinnati Tumour Registry was the ﬁ  rst to raise 
the possibility of an association between CsA use and the 
risk of malignancy, especially Non-Hodgkin’s Lymphoma 
(NHL) and Kaposi’s sarcoma (KS). Somewhat paradoxically 
though, the report also states that other skin cancers occurred 
less commonly than in those patients treated by conventional 
immunosuppression. The conclusion was that the neoplasms 
were probably not speciﬁ  c to CsA therapy but appeared to 
be a complication of immunosuppression in general. More 
recently a retrospective analysis of patients who developed 
malignancy following renal transplantation noted that, since 
the introduction of CsA, the incidence of tumor diagnosis 
had increased compared with the era of conventional immu-
nosuppression, but only in patients over 45 years at the time 
of renal transplantation. The most frequent cancers reported 
were skin and genitourinary (Tremblay et al 2002). Figures 
from the post-marketing surveillance study – which monitors 
organ transplant patients for 7 years after surgery, a total of 
10,454 patient years – showed that following transplanta-
tion, CsA increases the overall risk of malignancy two fold 
(Cockburn and Krupp 1989).
A retrospective study of 633 renal transplant patients, 
438 of whom received CsA as part of the immunosup-
pression regime, reported a signiﬁ  cantly higher number of 
malignancies developing in the four year follow-up period 
in those patients undergoing CsA use when compared with 
those undergoing conventional immunosuppression. Skin 
and genitourinary cancers were the most common malignan-
cies. An interesting point is that after an extended follow-up 
period for those patients treated with more conventional Clinical Ophthalmology 2007:1(4) 424
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immunosuppression, the rate of malignancy development 
increased (Schmidt et al 1996). An open randomized study 
took two cohorts of renal transplant patients that were random-
ized 1-year after transplantation. One group received low dose 
CsA and the second a normal dose group. They were followed 
for an average of 66 months. Of the initial 231 patients, 60 
developed malignancy, 37 in the normal dose group and 23 
in the low dose group (p   0.034), the majority being skin 
cancers. There was no evidence that halving trough blood 
CsA concentrations signiﬁ  cantly changed graft function or 
graft survival and that the low dose regimen was associated 
with fewer malignant disorders (Dantal et al 1998). McGeown 
et al (2000) showed that patients who received a higher dose 
of CsA (4.5 mg/kg/day) had a signiﬁ  cantly higher rate of 
tumor development than those on a dose of 3.4 mg/kg/day 
(p = 0.014). A recommendation was made to keep the dose of 
CsA to less than 3.5 mg/kg/day in long surviving, stable renal 
graft recipients in order to minimize the risk of developing 
malignancy. The commonest malignancies seen in the report 
were SCC, BCC and lymphoproliferative disease.
The multicentre Collaborative Transplant study (Opelz 
and Henderson 1993) published the rates of NHL develop-
ment in 52,775 transplant recipients and reported on the 
associated risk factors. They concluded that there were four 
factors in the development of NHL; heart rather than kid-
ney transplant, geography, antithymocyte/antilymphocyte 
globulin or the monoclonal anti-T-cell antibody OKT3 use 
and use of a combination of CsA and azathioprine (RR 1.47) 
however they did not ﬁ  nd any increase in NHL when CsA was 
used alone. A retrospective study by Libertiny et al (2001) 
followed 1501 patients that underwent renal transplant with 
immunosuppression over a 23 year period, again speciﬁ  cally 
looking at the rates of lymphoproliferative disease. The 
majority of their patients had a dose of CsA between 8 and 
10 mg per day, aiming for a trough level of 150–300 ng/ml. 
They concluded that over the years there had been two dis-
tinct changes in the rates of lymphoproliferative disease. The 
ﬁ  rst change occurred around the introduction of CsA into 
clinical practice after which an increase in the rate of PTLD 
was seen. The second increase in PTLD rate occurred around 
the early 1990s, completely independent of CsA use and may 
have reﬂ  ected a change in the pre-transplant transfusion rates. 
This study underlines the complexity of the subject and the 
differing conclusions that exist in the literature.
KS seems to be more severe after CsA immunosuppres-
sion rather than conventional immunosuppression. Farge 
(1993) reported upon the patients on the Groupe Collaboratif 
de Recherche en Transplantation de I’Ile de France (GCIF) 
registry. Of the 7923 patients analyzed, 0.52% developed KS 
in the follow up period. They found that KS was signiﬁ  cantly 
more common following liver transplantation and followed 
a more severe course in those patients treated by CsA 
rather than conventional immunosuppression. A report on 
50 patients who had developed malignancy following renal 
transplantation showed that KS was found in a higher pro-
portion of patients that had undergone immunosuppression 
with CsA than the more conventional treatment (Haberal et al 
2002). Montagnino et al (1994) reported on 13 from 820 renal 
transplant patients who developed KS following transplant. 
11 of the 13 were on CsA. In all patients immunosuppression 
was modiﬁ  ed and 9 of these 11 showed disease remission. 
Two patients died due to intestinal lesions but in these cases 
immunosuppression had been reintroduced following partial 
remission of the disease. An early report of KS (Little et al 
1983) showed regression of the disease when CsA dose was 
reduced to below 100 mg/day. Marcen et al (2003) performed 
a retrospective analysis of 793 patients who had undergone 
renal transplantation. Although there was no segregation of 
immunosuppression regimes, 7 of 8 patients who developed 
KS were treated with CsA. CsA was a signiﬁ  cant risk factor 
for the development of malignancy with an odds ratio of 4.45. 
A report of two cases of KS in kidney transplant patients 
who had been treated with azathioprine, steroids and CsA; 
during this treatment the Langerhans cells decreased and KS 
appeared. Discontinuation or reduction of the dosage of CsA 
led to complete regression of the illness. The Langerhans cells 
reappeared leading to the suggestion that CsA damages the 
immunological function of the epidermal Langerhans cells 
and that this was the primary factor in the development of 
KS (Bedani et al 1999).
Immunosuppression can be used in cases of severe 
rheumatoid arthritis (RA). Arellano and Krupp (1993) 
reported the results of a large study of over 1000 patients 
with RA who were treated with CsA. 17 patients developed 
a malignancy in the follow up period (which was in excess 
of 34 months) leading to the conclusion that although RA 
itself increases the risk of malignancy, the use of CsA 
leads to an additional risk, especially of lymphoprolifera-
tive disorders where the risk increased 3.5 fold. Of the 17 
who developed malignancy, only 2 received more than 
5.0 mg/kg/day CsA.
CsA is used extensively in the treatment of dermatologi-
cal disease. Grossman et al (1996) reported on 122 derma-
tology patients who had been treated with CsA for plaque 
psoriasis with doses ranging from 2.5 to 5 mg/kg/day for 
a treatment time of 3 to 76 months (median 21.5 months). Clinical Ophthalmology 2007:1(4) 425
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In this study, 5 patients developed a malignancy, two during 
the treatment period and three following discontinuation of 
CsA. This study had only a short follow-up time and may not 
have detected some cases that developed later. Marcil and 
Stern (2001) investigated 22 patients who were taking CsA 
for psoriasis, who had previously had PUVA phototherapy. 
There was a comparison made between the rate of SCCs that 
developed before CsA administration and the rate afterwards. 
CsA use signiﬁ  cantly increased the incidence of SCC above 
that from PUVA phototherapy alone. Unfortunately details 
of the dosages used were not reported. Paul et al (2003) 
published a prospective, 5-year observational study of 1252 
psoriatic patients treated by CsA and their malignancy rates. 
Malignancies were diagnosed in 3.8% of patients, 49% being 
skin malignancies and the majority being SCC. There was 
a six-fold higher incidence of skin malignancies than in the 
normal population with patients treated for more than 2 years 
having a higher risk of SCC development. The incidence of 
other malignancies was not signiﬁ  cantly higher than in the 
general population.
Non Hodgkin’s lymphoma development in those treated 
with CsA has prevalence 28 times higher than the general 
population (Cockburn and Krupp 1989). Compared with 
NHL developing after non-CsA immunosuppression, CsA 
lymphoma develops sooner, has a different presentation 
(more often involving lymph nodes and small intestine, 
rarely involving the brain) and was more likely to regress 
after reduction of immunosuppressive therapy (Cockburn and 
Krupp 1989). Kirby et al (2002) reported a case of cutane-
ous T cell lymphoma development following low dose CsA 
therapy initiated for atopic eczema. The tumor resolved on 
cessation of therapy. Koo et al (1992) reported the develop-
ment of a B-cell lymphoma following 8 months of CsA use 
(at a dose of less than 5 mg/kg/day), which was prescribed 
for recalcitrant psoriasis. The tumor presented 7 months after 
discontinuation of the treatment.
Other reports
Other reports have found that CsA use is associated with 
the development of malignancies and pre-malignant condi-
tions throughout the body. Several authors (Seshadri et al 
2001; Malouf et al 2004) have detailed the incidence of 
cervical intraepithelial neoplasia and papilloma infection 
in immunosuppressed patients in general. There is only a 
single case report (Grossman et al 1996) of cyclosporin 
mentioned speciﬁ  cally, however patients with uveitis do 
tend to be young and may be sexually active so this may 
be of particular concern. Ter Haar-van Eck et al (1995) did 
report that the incidence of abnormal cytology from smear 
testing in cyclosporin treated patients may be less than in 
more conventionally immunosuppressed patients.
Weinstein et al (2001) reported upon 5 patients who 
developed breast ﬁ  broadenomata following post-transplant 
CsA use, with an average dose of 265 mg/day for an 
average of 67 months. Similarly, Caetano Stefenon et al 
(2002) also reported the development of multiple, benign 
mammary nodules in an immunosuppressed patient on 
CsA. Piepkorn et al (1993) reported a case of Buschke-
Lowenstein penile carcinoma associated with intermittent 
CsA therapy for pustular psoriasis. There are also reports 
of conjunctival epithelial neoplasia (Macarez et al 1999), 
tonsillar carcinoma (Swoboda and Fabrizii 1993), laryngeal 
carcinoma (Namyslowski et al 1994) and genitourinary 
carcinomata (Maung et al 1985; Schmidt et al 1995) attrib-
utable to CsA use.
Studies showing no increased
risk of malignancy development 
with CsA use
Caillard’s (Caillard et al 2005) study of 25,127 post-transplant 
patients with respect to PTLD development revealed that 
overall, 1.4% of the cohort developed NHL. When compared 
to those patients taking Tacrolimus, CsA treated patients had 
a lesser risk of developing the disease (p = 0.02).
Van den Borne (1998) performed a retrospective cohort 
study of Rheumatoid Arthritis (RA) patients who received 
CsA in the Netherlands between 1984 and 1995. They 
matched each of the 208 patients enrolled in the study with 
2 control groups who had never received CsA. The ﬁ  ndings 
suggested that CsA treatment in RA patients does not increase 
the risk of malignancies in general or of lympho-proliferative 
malignancy or skin cancers in particular. These results have 
been questioned as the trial was open to signiﬁ  cant selection 
and assembly bias: only the index patients were thoroughly 
examined for pre-existing malignancy and the control group 
came from a different geographical area to the index cases.
Gruber (1994) compared the incidence of tumors devel-
oping in 1165 primary adult renal transplant recipients 
treated with a combination of azathioprine, prednisolone 
and antilymphocyte globulin with 722 patients receiving 
CsA as part of combined therapy. There was no signiﬁ  cant 
difference in the overall incidence of cancer (p = 0.41) or skin 
cancer (p = 0.97). Non-CsA-treated patients demonstrated a 
higher incidence of lymphoma (p = 0.05). They did report 
that the mean time to cancer occurrence was signiﬁ  cantly 
shorter in those patients who had been treated with CsA but Clinical Ophthalmology 2007:1(4) 426
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immunosuppressive regimen was not found to be a signiﬁ  cant 
independent prognostic indicator for cancer development. 
Indeed D’Costa et al (2003) recently reported that CsA 
inhibits the growth of a variety of lymphoid tumors in vitro, 
particularly in combination with irradiation.
London’s (London et al 1995) long term retrospective 
analysis of renal allograft patients, revealed that 70 out of 
918 patients developed a malignancy following transplant 
and subsequent immunosuppression. There was no evidence 
to support that there is an increased risk of cancer with CsA 
treatment over other immunosuppression regimes. It was 
conceded however, that the patients treated with CsA had a 
much shorter follow-up period.
Ophthalmic uses of systemic CsA 
and the risk of neoplasia
Patients suffering scleritis, Behçets disease, birdshot retino-
choroidopathy, pars planitis, sarcoidosis, Vogt-Koyanagi-
Harada (VKH) syndrome and sympathetic uveitis have all 
been successfully treated with systemic CsA. CsA has also 
been used to prevent corneal transplant rejection in high risk 
cases. Orsoni et al (2004) advocates the treatment of congeni-
tal syphilitic keratitis with CsA at a dose of 4 mg/kg/day (in 
combination with low dose steroid).
The majority of evidence in the non-ophthalmic literature 
shows that CsA causes malignancy and this is now a widely 
accepted risk – so how do we translate this to our ophthalmic 
practice? Many studies report the use of CsA in ophthalmol-
ogy but few mention the development of malignancy in their 
cohorts.
Young et al (2002) reported an interventional case series, 
which randomised patients with acute corneal graft rejection 
into one of two groups concerned with the dose of CsA in 
conjunction with topical steroid and intravenous methyl-
prednisolone. They found that a low dose CsA regime was 
less effective in reversing the rejection episode and there was 
no report of any malignancy development. A similar study 
by Poon et al (2001) with respect to prevention of rejection 
in high risk keratoplasties also did not show any malignancy 
development but they did conclude that CsA did not give a 
signiﬁ  cantly increased beneﬁ  t over conventional therapy in 
this situation.
Wakeﬁ  eld and McCluskey (1991) reported a study of 
22 patients with sight threatening uveitis whose disease 
had previously been refractory to treatment. Nineteen 
patients showed significant clinical improvement after 
initial treatment with CsA. Side effects were common with 
doses greater than 5 mg/kg/day. Muftuoglu et al (1987) 
reported improvements in Behçets disease – both ocular 
and mucocutaneous symptoms – using an oral dose of 10 
mg/kg/day with similar side effects. Neither studies com-
mented upon any malignancy development with the treat-
ment. Nussenblatt et al (1985) reported long term follow 
up of 52 uveitis patients treated with CsA and speciﬁ  cally 
reported “….We did not observe opportunistic infections 
nor CsA associated neoplasms in our patients.” Vitale et al 
(1996) reported on 92 eyes with uveitis of various etiologies 
that had been treated with low-dose CsA (2.5–5.0 mg/kg 
daily) alone or in combination with prednisolone and/or 
azathioprine. The CsA was discontinued in ﬁ  ve patients due 
to nephrotoxicity, systemic hypertension or constitutional 
intolerance to the drug. Again there was no mention of any 
malignancy development.
There are two case reports of malignancy developing 
following CsA use in an ophthalmology patient; the devel-
opment of a malignant rhabdoid tumor in a patient treated 
with CsA for Behçets disease (Muramatsu et al 1998) and a 
patient who developed a gastric Epstein-Barr virus induced 
B-cell lymphoma following systemic CsA treatment, which 
was initiated as prophylaxis for a high risk keratoplasty 
(Algros et al 2002).
Topical cyclosporin
In any type of ocular surface disease a downward spiral 
of increasing inﬂ  ammation and damage is present, mean-
ing topical CsA may be an effective alternative to topical 
steroids in these conditions. Although topical CsA has been 
investigated and reported since the 1980’s, due to problems 
with sterility, pH, particles and its inherent lipophilia only 
recently has a commercially available product been made 
available (Restasis, cyclosporine ophthalmic emulsion 
0.05%, Allergan Inc).
The early study showed that topical 2% cyclosporin pen-
etrated the aqueous to noticeable levels but without detectable 
levels in the serum (Diaz-Llopas and Menezo 1989). This 
has been contradicted by Zhao and Jin (1993) who showed 
that small amounts of CsA were found in the blood following 
the use of 0.5% CsA. This is the only report of blood serum 
levels of CsA being elevated and current animal studies 
show that systemic absorption is negligible (TangiLiu and 
Acheampong 2005).
The main indication for topical CsA is for relief of dry 
eyes due to a combination of its immunomodulatory effects 
and possibly direct lacrimogenic effects. Topical CsA is also 
advocated for the use in; atopic and vernal keratoconjunc-
tivitis, Thygeson’s superﬁ  cial punctate keratitis, ligneous Clinical Ophthalmology 2007:1(4) 427
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conjunctivitis and conjunctival involvement with lichen 
planus (Holland et al 1993; Tatlipinar and Akpek 2005).
There are a wealth of studies relating to studies of the 
safety and efﬁ  cacy of topical CsA however, there are no 
reported cases of malignancy associated with the topical 
formulation. We would expect that local administration 
of CsA to have low risk of systemic tumor development 
due to the negligible absorption. In contrast to the report 
of conjunctival neoplasia development following systemic 
CsA (Macarez et al 1999), a recent report (Tunc and Erbilen 
2006) advocates the use of topical CsA (in conjunction with 
Mitomycin C) for the treatment of ocular surface squamous 
cell carcinoma.
Comparison of malignancy 
potential of CsA with other 
immunosuppressants used
in ophthalmology
Other T-cell/calcineurin inhibitors
T-cell inhibitors have long been linked with post transplant 
malignancies. Tacrolimus has a similarly complex onco-
genesis to cyclosporin. In murine models it has been shown 
to cause a 5-fold increase in lymphoproliferative disease in 
association with persistent herpes viral infection, to induce 
apoptosis in transgenic models studying Fas/Fas ligand inter-
actions, and to induce TGF-β expression. Conversely it has 
been shown to inhibit intercellular adhesion molecules and 
thus prevent angiogenesis in cell culture. Although initial high 
relative risks of lymphoproliferative disease were reported 
with tacrolimus use, these were later attributed to inexperience 
with the agent and overaggressive dosing. A cohort study of 
children with post-transplant lymphoproliferative disorder 
(PTLD) compared to those without, found tacrolimus (in 
combination with mycophenolate) was not a risk factor in its 
development (Dharnidharka et al 2002) and it is argued to be 
safer than cyclosporin (Reichenspurner 2005).
Antimetabolites
Antimetabolites, particularly azathioprine have long been 
associated with a wide variety of neoplasms. The age-
adjusted relative risk of developing any malignancy with 
its use has been calculated at 0.85 in multiple sclerosis 
patients (Amato et al 1993). A cohort study of 1000 renal 
transplant recipients reported patients on azathioprine had 
a lower cumulative incidence of tumors than those on CsA 
regimes (McGeown et al 2000), however the increased risk of 
nonmelanotic skin malignancies (particularly squamous cell 
carcinoma) posttransplantation is largely thought attributable 
to azathioprine use (Kasiske et al 2004). Although there have 
been an increasing number of case reports of lymphoma in 
rheumatoid arthritis patients treated with methotrexate, some 
with spontaneous remission upon treatment cessation, a large 
prospective study failed to establish a causal relationship 
(Wolfe and Michaud 2004).
Alkylating agents
Most of the data supporting the increased malignancy poten-
tial of alkylating agents has been in conditions with intrinsic 
malignancy risk. However in a randomized controlled trial 
of 431 patients with polycythaemia vera, the rate of acute 
leukaemia was 13.5-fold greater with chlorambucil treatment 
than with phlebotomy or radioactive phosphorus and appeared 
to be dose related (Berk et al 1981). A case-controlled study 
of 238 patients with rheumatoid arthritis attributed a 1.5-fold 
increase of bladder, skin and myeloproliferative malignancies 
with cyclophosphamide use (Radis et al 1995). This effect 
was associated with longer duration of treatment, and in the 
case of bladder cancer appeared to be long-term.
Anti-TNF therapy
Tumor necrosis factor (TNF) is important in natural killer cell 
and CD8 lymphocyte-mediated destruction of tumor cells, 
however conversely tumor promoting effects of TNF have 
also been described. Anti-TNF antibody therapy has been 
linked in particular to basal cell carcinoma and lymphoma. 
A meta-analysis of randomized trials of rheumatoid arthritis 
patients comparing inﬂ  iximab and adalimumab treatment 
versus placebo calculated a pooled odds ratio for malignancy 
of 3.3 times higher in the anti-TNF group compared with the 
control group, with a dose-dependent relationship (Bongartz 
et al 2006). A prospective cohort study of rheumatoid 
arthritis patients suggested an increased risk of lymphoma 
in those receiving anti-TNF therapies over methotrexate or 
no disease-modifying drugs. The standardized incidence 
ratio was higher with etanercept than inﬂ  iximab although 
differences were slight and conﬁ  dence intervals overlapped 
(Wolfe and Michaud 2004). Etanercept was recently statisti-
cally signiﬁ  cantly linked to solid tumors but not to basal or 
squamous cell carcinomas in a randomized trial of patients 
with Wegener’s granulomatosis comparing etanercept plus 
cyclophosphamide therapy to cyclophosphamide alone 
(WGET Research Group 2005).
In contrast, newer immunosuppressive agents such as 
mycophenolate and sirolimus appear to have antiproliferative 
properties. This has been demonstrated with mycophenolate Clinical Ophthalmology 2007:1(4) 428
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against leukaemias and lymphomas both in vitro and in vivo 
and in colon and prostate carcinoma cells. The agent has been 
shown to suppress glycosylation and expression of several 
adhesion molecules key to solid tumor dissemination, and to 
inhibit adhesion of colon adenocarcinoma cells to endothelial 
cells. These properties are expressed in population analyses 
of transplant recipients where mycophenolate has a protec-
tive effect within immunosuppression regimes (Cherikh 
et al 2003; Dharnidharka et al 2002). Indeed higher doses of 
mycophenolate confer lower relative skin cancer risk (Wang 
et al 2004). Similarly, sirolimus (rapamycin) has remarkable 
antineoplastic properties, with reduced incidences of malig-
nancies both alone and in combination with CsA/tacrolimus 
in transplant recipients (Kauffman et al 2005; Kreis et al 
2004). It has also been shown to induce resolution of Kaposi’s 
sarcoma (Stallone et al 2005).
Comment and recommendations
Many of the studies used to formulate this review have 
been limited by their design and study population. The 
majority of studies have been retrospective, specific to 
their speciality, mainly with renal transplant patients. 
Although it is difficult to extrapolate the findings of these 
studies to ophthalmic practice, two key issues emerge. 
The most striking feature that is evident is that the rate 
of neoplasia increases with duration of treatment and 
follow-up. Secondly, there appears to be a relationship 
between the dose of CsA used and the development of 
malignancy (Cockburn and Krupp 1989; Arellano and 
Krupp 1993; Farge 1993; Dantal et al 1998; McGeown 
et al 2000).
Although there are scarce reports of malignancy fol-
lowing CsA use in ophthalmic practice, all of the studies 
regarding CsA use in ophthalmology have been concerned 
with clinical outcome rather than development of malig-
nancy. The doses of CsA used in ophthalmic practice are in 
the same range as many of the studies reporting signiﬁ  cant 
malignancy rates, but the treatment time and, importantly, 
the follow-up times have been much less.
What is required is a cohort study of CsA use in ophthal-
mic disease with particular reference to the development of 
malignancy. Only then can the full risks be weighed against 
the beneﬁ  ts of CsA. The rate of tumor development with 
prolonged CsA should be of concern to the ophthalmic 
community. After thorough examination of the published 
literature, we propose some recommendations for the assess-
ment of patients who are to be considered for treatment 
with CsA.
Recommendations
1.  Relative contraindications to the use of CsA should 
include current or past skin malignancy (except for basal 
cell carcinoma) and lymphoproliferative disease. A his-
tory of remote malignancy should be treated as a cause 
for concern.
2.  Premalignant conditions such as leukoplakia, monoclonal 
paraproteinaemia and myelodysplastic syndrome should 
be excluded.
3.  Before commencing treatment with CsA, patients should 
be examined for skin malignancy (for SCC and KS) and 
screened for potential lymphoproliferative disease by 
enquiring for suggestive symptoms and examination for 
lymphadenopathy and hepatosplenomegaly.
4.  Whilst undergoing therapy, monitoring should continue 
for the development of skin tumors and lymphoprolifera-
tive disorders.
5.  The presentation of lymphoproliferative disorders can 
range from tonsillar hyperplasia to frank nodules of internal 
organs or lymph nodes, in addition, the development of 
suspicious symptoms such as fever, night sweats and sub-
stantial weight loss would warrant further investigation.
6.  Full investigation for lymphoproliferative disease 
includes computerised tomography (CT) of the chest, 
abdomen and pelvis and this should be performed if the 
diagnosis is suggested.
7.  Self-monitoring by the patient is also clearly important 
and should be encouraged.
8.  Patients should be advised to use a sun screen when 
exposed to the sun.
9.  Although CsA related malignancy tends to be either 
of skin or the lymphoproliferative system it should be 
remembered that other malignancies can develop. Rou-
tine screening, especially cervical screening, should be 
enforced rigorously.
10. The use of condoms should be actively encouraged in the 
sexually active patient.
11. The development of malignancy attributable to CsA can 
present following discontinuation of its use, so arrange-
ments for follow-up examination should be made for at 
least 5 years.
12. The use of minimal effective dosages may reduce the 
carcinogenic potential of CsA.
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